tiprankstipranks
Resmed (RMD)
NYSE:RMD

Resmed Stock Forecast & Price Targets

661 Followers
See the Price Targets and Ratings of:

Analyst Rating Consensus

Moderate Buy
10Ratings
4 Buy
6 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Resmed
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

Analyst Price Target on RMD

Average Price Target

$216.00
▼(-8.63% Downside)
Based on 10 Wall Street analysts offering 12 month price targets for Resmed in the last 3 months. The average price target is $216.00 with a high forecast of $276.00 and a low forecast of $27.02. The average price target represents a -8.63% change from the last price of $236.41.
Highest Price Target$276.00Average Price Target$216.00Lowest Price Target$27.02
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Upgrade Banner
Goldman Sachs
Buy
Upgraded
Goldman Sachs upgrades ResMed (RMD) to BuyGoldman Sachs analyst Chris Cooper upgraded ResMed (NYSE: RMD) from Neutral to Buy.
Macquarie
Buy
Upgraded
ResMed upgraded to Outperform from Neutral at MacquarieResMed upgraded to Outperform from Neutral at Macquarie
Oppenheimer
$312.00
Buy
31.97%
Upside
Reiterated
Oppenheimer Sees Apnimeds Ph2 Results Worth Watching for ResMed (RMD)The analyst stated "If results can continue to be replicated even in certain phenotypes of OSA or AHI categories, the appeal of a potential once-daily oral therapy as a first-line therapy in OSA remains an interesting story to watch."
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
PRVAPrivia Health Group
RXDXPrometheus Biosciences
ROIVRoivant Sciences
ABCLAbCellera Biologics
NRIXNurix Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

FAQ

What is RMD’s average 12-month price target, according to analysts?
Based on analyst ratings, Resmed’s 12-month average price target is $216.00.
    What is RMD’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for RMD, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

        What's Included in PREMIUM?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis